Company profile
Oncotelic Therapeutics, Inc. CIK 908259
Ticker
OTLC (OTC)
Industry
Pharmaceutical Preparations
Headquarters
Aguora Hills, CA 91301
Fiscal year end
2025 (FY)
Key Financials
Revenue
—
Net income
$249.28M
Total assets
$393.09M
Total liabilities
$131.36M
Stockholders' equity
$262.76M
Cash & equivalents
—
Operating income
-$3.19M
Operating cash flow
-$1.38M
Capital expenditures
—
Fiscal year 2025, via 10-K filed 2026-04-15. A dash means this figure wasn't reported in the source filing under a field State Ledger recognizes - not that the value is zero.
Financial Performance
Operating margin
—
Net margin
—
Free cash flow
—
Free cash flow margin
—
Liabilities / assets
33.4%
Equity / assets
66.8%
CapEx / revenue
—
Operating cash flow / net income
-0.01×
Derived from the fiscal year 2025 figures above. These metrics are mathematical calculations and do not represent a rating or assessment of the company.
Financial History
Fiscal yearRevenueNet incomeAssetsLiabilitiesEquity
2025
—
$249.28M
$393.09M
$131.36M
$262.76M
2024
—
-$4.52M
$26.68M
$19.20M
$8.25M
2023
$70.0K
-$7.90M
$30.01M
$18.40M
$12.13M
2022
—
$5.09M
$36.12M
$16.92M
$19.41M
2021
—
-$9.39M
$23.61M
—
$7.96M
Company Details
SIC code
2834
State of incorporation
DE
Active filer
Yes
Most recent SEC filing
Form 10-Q
2026-08-13
Financials filed via
Form 10-K
filed 2026-04-15
"Most recent SEC filing" may differ from the filing used for the financial figures above.
Location
Aguora Hills, CA 91301
Data & Methodology
SEC EDGAR submissions API (identity, collected Sep 19, 2026, 15:11 UTC) and SEC XBRL Company Facts API (financials, collected Sep 26, 2026, 15:14 UTC) · figures as originally filed, not restated · a dash always means a value wasn't reported, never a real zero.